checkAd
    Startseite > Aktien > TriSalus Life Sciences > Nachrichten
    TriSalus Life Sciences Aktie
    6,5100
     
    USD
    -5,92 %
    -0,4100 USD
    Letzter Kurs 08.06.24 Nasdaq
    6,5100
     
    USD
    100 STK
    Geldkurs 07.06.24
    6,8000
     
    USD
    100 STK
    Briefkurs 07.06.24
    ISIN: US89680M1018 · WKN: A3EP5W · SYM: TLSI · USA

    Neueste Nachrichten

    TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
    03.06.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
    24.05.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Reports Q1 2024 Financial Results and Business Update
    15.05.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
    07.05.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
    06.05.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives
    30.04.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
    01.04.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
    26.03.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
    21.03.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
    11.03.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
    07.03.24 · Business Wire (engl.) · TriSalus Life Sciences
    TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
    29.02.24 · Business Wire (engl.) · TriSalus Life Sciences